Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays Elecsys and Lumipulse with amyloid PET status

摘要

We evaluated for two novel automated biomarker assays how cerebrospinal fluid (CSF) amyloid beta (Aβ)1– 42‐ratios improved the concordance with amyloid positron emission tomography (PET) positivity compared to Aβ1– 42 alone.